Compare Fresenius Kabi Onco. with Aventis Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs SANOFI INDIA - Comparison Results

FRESENIUS KABI ONCO.     Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. SANOFI INDIA FRESENIUS KABI ONCO./
SANOFI INDIA
 
P/E (TTM) x 22.1 38.3 57.8% View Chart
P/BV x 3.1 6.7 46.4% View Chart
Dividend Yield % 0.0 1.3 -  

Financials

 FRESENIUS KABI ONCO.   SANOFI INDIA
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
SANOFI INDIA
Dec-18
FRESENIUS KABI ONCO./
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1766,840 2.6%   
Low Rs794,630 1.7%   
Sales per share (Unadj.) Rs37.71,203.1 3.1%  
Earnings per share (Unadj.) Rs5.1165.3 3.1%  
Cash flow per share (Unadj.) Rs6.7209.9 3.2%  
Dividends per share (Unadj.) Rs084.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs42.5963.6 4.4%  
Shares outstanding (eoy) m158.2323.03 687.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.8 70.8%   
Avg P/E ratio x25.034.7 72.0%  
P/CF ratio (eoy) x18.927.3 69.3%  
Price / Book Value ratio x3.06.0 50.3%  
Dividend payout %050.8 0.0%   
Avg Mkt Cap Rs m20,135132,078 15.2%   
No. of employees `0001.23.3 34.9%   
Total wages/salary Rs m7034,068 17.3%   
Avg. sales/employee Rs Th5,176.28,393.8 61.7%   
Avg. wages/employee Rs Th610.41,232.4 49.5%   
Avg. net profit/employee Rs Th699.61,153.0 60.7%   
INCOME DATA
Net Sales Rs m5,96327,708 21.5%  
Other income Rs m18897 2.0%   
Total revenues Rs m5,98128,605 20.9%   
Gross profit Rs m1,4306,235 22.9%  
Depreciation Rs m2581,027 25.1%   
Interest Rs m-267 -371.4%   
Profit before tax Rs m1,2166,098 19.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m3422,292 14.9%   
Profit after tax Rs m8063,806 21.2%  
Gross profit margin %24.022.5 106.6%  
Effective tax rate %28.137.6 74.9%   
Net profit margin %13.513.7 98.4%  
BALANCE SHEET DATA
Current assets Rs m5,10215,922 32.0%   
Current liabilities Rs m2,3856,235 38.3%   
Net working cap to sales %45.635.0 130.3%  
Current ratio x2.12.6 83.7%  
Inventory Days Days15064 235.7%  
Debtors Days Days11321 542.9%  
Net fixed assets Rs m5,1487,539 68.3%   
Share capital Rs m158230 68.8%   
"Free" reserves Rs m6,55621,962 29.8%   
Net worth Rs m6,73222,192 30.3%   
Long term debt Rs m9520-   
Total assets Rs m10,38829,839 34.8%  
Interest coverage x-45.8872.1 -5.2%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.9 61.8%   
Return on assets %7.512.8 58.8%  
Return on equity %12.017.2 69.8%  
Return on capital %14.627.5 53.1%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,2987,587 69.8%   
Fx outflow Rs m1,7727,145 24.8%   
Net fx Rs m3,525442 797.6%   
CASH FLOW
From Operations Rs m1,2743,739 34.1%  
From Investments Rs m-1,204-731 164.7%  
From Financial Activity Rs m-196-1,972 9.9%  
Net Cashflow Rs m-1261,036 -12.2%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 81.0 60.4 134.1%  
Indian inst/Mut Fund % 0.3 14.4 2.1%  
FIIs % 9.6 14.6 65.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 10.5 86.7%  
Shareholders   42,599 15,184 280.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   WYETH LTD  PIRAMAL ENTERPRISES  NATCO PHARMA  SUN PHARMA  IPCA LABS  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Open Marginally Higher; Healthcare Stocks Witness Buying(09:30 am)

Asian share markets are trading on a negative note today as Japanese and Hong Kong shares show losses. The Nikkei 225 is down 0.79% while the Hang Seng is down 1.73%.

Related Views on News

SANOFI INDIA Announces Quarterly Results (1QFY20); Net Profit Down 2.2% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, SANOFI INDIA has posted a net profit of Rs 974 m (down 2.2% YoY). Sales on the other hand came in at Rs 7 bn (up 9.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (4QFY19); Net Profit Up 12.6% (Quarterly Result Update)

May 8, 2019 | Updated on May 8, 2019

For the quarter ended March 2019, SANOFI INDIA has posted a net profit of Rs 929 m (up 12.6% YoY). Sales on the other hand came in at Rs 7 bn (up 16.1% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA 2017-18 Annual Report Analysis (Annual Result Update)

Apr 16, 2019 | Updated on Apr 16, 2019

Here's an analysis of the annual report of SANOFI INDIA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SANOFI INDIA. Also includes updates on the valuation of SANOFI INDIA.

SANOFI INDIA Announces Quarterly Results (3QFY19); Net Profit Up 4.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, SANOFI INDIA has posted a net profit of Rs 793 m (up 4.3% YoY). Sales on the other hand came in at Rs 7 bn (up 8.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

More Views on News

Most Popular

Is Hawkins Set to Become Our Next Superhero Stock?(The 5 Minute Wrapup)

Nov 1, 2019

After PI Industries, Hawkins has put up a stellar show so far.

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

What to Buy at Sensex 40,000(The 5 Minute Wrapup)

Nov 4, 2019

Should you invest in high-quality, safe stocks or make some contrarian bets in the smallcap space?

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 8-QTR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS